Refine
Has Fulltext
- yes (102)
Is part of the Bibliography
- yes (102)
Year of publication
Document Type
- Journal article (102) (remove)
Language
- English (102) (remove)
Keywords
- therapeutic drug monitoring (4)
- chemistry (3)
- human (3)
- pharmacokinetics (3)
- polyphenols (3)
- population pharmacokinetics (3)
- positron emission tomography (3)
- synthesis (3)
- ARONJ (2)
- Alzheimer’s disease (2)
- Chemie (2)
- Ernährung (2)
- Medizin (2)
- S-ADAPT (2)
- allometric scaling (2)
- azobenzenes (2)
- body composition (2)
- body size (2)
- butyrylcholinesterase (2)
- capillary electrophoresis (2)
- crystal structure (2)
- cystic fibrosis patients (2)
- cytochrome P450 3A4 (CYP3A4) (2)
- dendritic cells (2)
- drug design (2)
- drugs (2)
- drug–drug interactions (DDIs) (2)
- estrogens (2)
- gene expression (2)
- graft versus host disease (2)
- healthy volunteers (2)
- human breast (2)
- kinetics (2)
- leishmaniasis (2)
- medicine (2)
- multiple linear regression (2)
- natural products (2)
- norepinephrine transporter (2)
- nutrition (2)
- octopamine (2)
- osteoarthritis (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- physiologically based pharmacokinetic (PBPK) modeling (2)
- protein binding (2)
- solubility (2)
- strategy (2)
- structure-activity relationships (2)
- sympathetic nervous system (2)
- therapy (2)
- thermogenesis (2)
- 1 (1)
- 2,5-diketopiperazines (1)
- 2-Thiazaphospholidines (1)
- 2-chloro (1)
- 2-halo (1)
- 2-imino- (1)
- 3 (1)
- 77-LH-28-1 (1)
- AAA+ ATPase p97 (1)
- AChE inhibitor (1)
- AD mouse modele (1)
- ADAMTS (1)
- AGP (1)
- Akt/PKB (1)
- Alzheimer's diseas (1)
- Alzheimer's disease (1)
- Alzheimer′s disease (1)
- Analytical Quality by Design (1)
- Asymmetrie (1)
- Aziridines (1)
- BRAF mutation (1)
- Benzimidazole (1)
- CAD detection (1)
- CO‐releasing molecules (CORMs) (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cabozantinib (1)
- Candida albicans (1)
- Candida auris (1)
- Cecropia telenitida (1)
- Charged aerosol detector (CAD) (1)
- Citrus (1)
- Commercial preparations (1)
- Contaminants (1)
- Cutaneous leishmaniasis (1)
- Enterobacteriaceae (1)
- Eriodictyon californicum (1)
- Escherichia coli (1)
- FV45 (1)
- Fatty acids (1)
- Flavonoids (1)
- G-protein coupled receptor (1)
- GABA (1)
- GABAB receptor agonists (1)
- GABA\(_{A}\) receptor (1)
- GABA\(_{B}\) (1)
- Geschichte (1)
- Gradient boosted trees (GBT) (1)
- HNSCC (1)
- HPLC–MS (1)
- High-performance liquid chromatography (HPLC) (1)
- Hydrogen-deuterium (1)
- IR (1)
- Ibuprofen (1)
- Imidates (1)
- Imidoyl halides (1)
- Impact-Faktor (1)
- In vivo studies (1)
- Klebsiella pneumoniae (1)
- Kohlenhydrate (1)
- LC-ESI/MS/MS (1)
- LC-MS/MS (1)
- LpxC inhibitors (1)
- MRONJ (1)
- MYCNv (1)
- Manganese Carbonyl ligands (1)
- Melatonin (1)
- Microglia (1)
- Mitsunobu (1)
- Natural product hybrids (1)
- ONJ (1)
- Osmunda regalis (1)
- PET (1)
- Paeonia (1)
- Phenolic acids (1)
- Positronen-Emissions-Tomografie (1)
- Pycnogenol (1)
- Quantitative structure-property relationship modeling (QSPR) (1)
- RESP model (1)
- Red Sea (1)
- Robuvit\(^®\) (1)
- Ruxolitinib (1)
- SPECT (1)
- Schistosomiasis (1)
- Spectrofluorimetry (1)
- Staphylococcus aureus (1)
- Streptomyces axinellae (1)
- Synthesis (1)
- T cell (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TDDFT (1)
- Tanzania (1)
- Tryptophan (1)
- V. wallichii (1)
- Valeriana wallichii (1)
- Wissenschaftliches Arbeiten (1)
- Xanomeline (1)
- \(^{1}\)HNMR (1)
- absolute bioavailability (1)
- acebutolol (1)
- acetic acid (1)
- acetones (1)
- acetonitrile (1)
- acetylcholinesterase (1)
- acid value (1)
- acids (1)
- activation (1)
- additive manufacturing (1)
- afatinib (1)
- affinity (1)
- agar diffusion test (1)
- alignment (1)
- allergic rhinitis (1)
- allosteric modulation (1)
- amber codon suppression (1)
- amber light (1)
- ampicillin (1)
- amyloid beta (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- anti-inflammatory activity (1)
- anti-proliferative effects (1)
- anti-schistosomal activity (1)
- anti-trypanosomal (1)
- antibacterial activity (1)
- antibacterials (1)
- antibiotic bone concentration (1)
- antifungal drug (1)
- antileishmanial (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiviral agents (1)
- at-home sampling (1)
- autoinjector (1)
- autophagy (1)
- baclofen (1)
- baclofen homologues (1)
- beta-lactam (1)
- beta-lactam antibiotics (1)
- bile (1)
- bile salt (1)
- binding analysis (1)
- bio-orthogonal chemistry (1)
- bioactivity (1)
- biochemical simulations (1)
- biocide polyhexamethylene biguanide (1)
- biodiversity (1)
- bioisosterism (1)
- biophysics (1)
- biosensor (1)
- biosynthesis (1)
- bitopic hybrid ligands (1)
- bitopic ligand (1)
- blood brain barrier (1)
- blood plasma (1)
- boat conformation (1)
- bone marrow (1)
- bronchial tissue (1)
- brucei (1)
- caffeic acid bornyl ester (1)
- carbamate (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cartilage (1)
- cecropia telenitida (1)
- cefotiam (1)
- cell metabolism (1)
- cells (1)
- cerebEND cells (1)
- charged aerosol detector (1)
- chemotherapy (1)
- chenopodium quinoa (1)
- chiral (1)
- chiral resolution (1)
- chiral separation (1)
- cholinergic system (1)
- cholinesterases inhibitors (1)
- circular dichroism (1)
- citrus (1)
- click chemistry (1)
- clinical study (1)
- cofactors (biochemistry) (1)
- cold stress (1)
- colloid (1)
- commercial preparations (1)
- complementary medicine (1)
- computational chemistry (1)
- contaminants (1)
- crithidia fasciulata (1)
- cyclodextrins (1)
- cysteine protease (1)
- cytokine modulation (1)
- cytokine production (1)
- cytotoxicity (1)
- dabrafenib (1)
- decafluoroazobezene (1)
- dehydration (1)
- derivates (1)
- design of experiments (1)
- detector (1)
- diabetes (1)
- diketopiperazines (1)
- discovery (1)
- dissolution (1)
- dissolution rates (1)
- drug impurities (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-delivery systems (1)
- electroactive (1)
- electrohydrodynamic (1)
- emulsions oil-in-water (1)
- enantiomers (1)
- endothelium (1)
- enoyl-ACP reductase inhibitors (1)
- enterohepatic recirculation (1)
- enzyme kinetics (1)
- enzymes (1)
- ephedrine (1)
- epitope mapping (1)
- ester value (1)
- ethanol (1)
- ethers (1)
- eugenyl cinnamate (1)
- exchange reaction (1)
- excipient (1)
- experimental visceral leishmaniasis (1)
- extraction (1)
- fatty acids (1)
- fenoterol (1)
- field testing (1)
- flavonoid (1)
- flavonoids (1)
- fluorescence resonance energy transfer (1)
- fluorescent ligands (1)
- fluorescent probes (1)
- fluorine-18 (1)
- fluoroquinolone (1)
- fluticasone propionate (1)
- flux (1)
- forms (1)
- fragment screening (1)
- fragment-based design (1)
- gallotannins (1)
- gastrointestinal (1)
- genetics (1)
- gentamicin sulfate (1)
- glucos metabolism (1)
- glucose (1)
- glutathione (1)
- glycocalyx (1)
- glycolytic flux control (1)
- gradient HPLC–UV (1)
- gut microbiota; bioactivation; polyphenols; complex carbohydrates; tryptophan (1)
- hMSC-TERT (1)
- head and neck carcinoma (1)
- heart failure (1)
- high performance liquid chromatography (1)
- high-resolution tandem mass spectrometry (1)
- high-throughput screening (1)
- histamine (1)
- history (1)
- homodimerization (1)
- homology modeling (1)
- honeybee (1)
- honeybees (1)
- human receptor kinetics (1)
- hybrid molecules (1)
- hydnocarpin (1)
- hydrogels (1)
- hydrogen bonding (1)
- hydrogen bonding mycobacterium tuberculosis (1)
- hydrolysis (1)
- hydroxy-dabrafenib (1)
- hypoxia (1)
- hysterectomy (1)
- imaging (1)
- impurity profiling (1)
- in vitro (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vitro-in vivo correlation (1)
- in vivo dissolution (1)
- information technology (1)
- internal transcribed spacer 2 (1)
- intramolecular Michael addition (1)
- intranasal corticosteroids (1)
- intrinsic metabolism (1)
- invasion (1)
- iodine value (1)
- ipratropium bromide (1)
- isolation (1)
- isomerization (1)
- isosteviol sodium (1)
- jaw bone (1)
- kappa-B activation (1)
- ketamine (1)
- kinase inhibitors (1)
- leaves (1)
- linear discriminant analysis (1)
- liquid chromatography electrospray ionization tandem mass spectrometry (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography-mass spectrometry (1)
- liver impairment (1)
- maceration (1)
- macrophages (1)
- magnesium stearate (1)
- manufacturer (1)
- marine metagenomics (1)
- marine natural products (1)
- marine organisms (1)
- marine sponge (1)
- maritime pine bark extract (1)
- matrix metalloproteinases (1)
- medicine authentication tools (1)
- melanoma (1)
- melatonin (1)
- metabolic glycoengineering (1)
- metabolic network model (1)
- metabolism (1)
- metastasis (1)
- micelles (1)
- microscopy (1)
- mobile apps (1)
- modified monosaccharides (1)
- molecular mechanics (1)
- molecular systematics (1)
- multicomponent Ugi-type reaction (1)
- muscarinic M1 receptor (1)
- muscarinic acetylcholine receptors (1)
- muscarinic receptors (1)
- natural product (1)
- natural product hybrids (1)
- nerve agent (1)
- neuroblastoma cell (1)
- neuroprotection (1)
- neuroprotectivity (1)
- nicotinic receptors (1)
- nitric oxide (1)
- non-racemic (1)
- nonhuman primates (1)
- novel nepetolactone derivative (1)
- nuclear cardiology (1)
- oak wood (1)
- oak wood extract (1)
- obtusifolia bertol (1)
- octopamine receptors (1)
- oleanane saponins (1)
- online monitoring system (1)
- opioid ligands (1)
- opioid receptors (1)
- oral anticancer drugs (1)
- oral bioavailability (1)
- oral drug absorption (1)
- oral microbiome (1)
- osimertinib (1)
- oxidative stress (1)
- oxime (1)
- oxygen (1)
- oxytosis/ferroptosis (1)
- parasite (1)
- paromomycin (1)
- patch clamp recording (1)
- pefloxacin (1)
- pentacyclic triterpene (1)
- peptide sensors (1)
- peptide stapling (1)
- perfluoroarylation (1)
- peri-implant disease (1)
- personalized antimicrobial therapy (1)
- pharmaceutical analysis (1)
- pharmacological evaluation (1)
- phosphoglycolate phosphatase (1)
- photocontrol (1)
- photopharmacology (1)
- phylogenetic tree (1)
- phylogeny (1)
- phytochemicals (1)
- pine bark extract (1)
- piperacillin/tazobactam (1)
- plant extract (1)
- plants (1)
- plasma proteins (1)
- podophyllotoxin (1)
- polymer drug interaction (1)
- polymer processing (1)
- polymers (1)
- polysorbate 80 (1)
- posaconazole (1)
- post-operative recovery (1)
- post-surgery recovery (1)
- pressurized microwave‐assisted extraction (1)
- principal component analysis (1)
- proliferation (1)
- propionate (1)
- protease inhibition (1)
- protease inhibitors (1)
- proteasome system (1)
- protein engineering (1)
- psidium guajava; (1)
- pulmonary absorption (1)
- purification (1)
- pyridobenzodiazepine (1)
- qPCR (1)
- quality evaluation (1)
- quantitative 1H NMR (1)
- quantum mechanics (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- randomized controlled study (1)
- rat study (1)
- red blood cells (1)
- red fruit oil (1)
- renal cell carcinoma (1)
- renin-angiotensin system (1)
- replica-exchange molecular dynamics (1)
- required hydrophilic–lipophilic balance (1)
- resistance (1)
- response surface (1)
- ribosomal RNA (1)
- ruxolitinib (1)
- sacha inchi oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- schistosoma (1)
- schistosomula (1)
- screening (1)
- secondary structure (1)
- secretion (1)
- sensory chewing gums (1)
- serjanic acid (1)
- serum (1)
- short-range order (1)
- silybin (1)
- simulated intestinal fluid (1)
- single-molecule microscopy (1)
- sisomicin (1)
- solid-state NMR spectroscopy (1)
- spectrofluorimetry (1)
- spray (1)
- staphylococcus aureus (1)
- sterubin (1)
- streptomyces (1)
- structural elucidation (1)
- structure-activity relationship (1)
- structure–activity relationships (1)
- substandard and falsified medicines (1)
- synovial fluid (1)
- system (1)
- tacrine (1)
- tetromycin (1)
- thin-layer chromatography (1)
- thymyl cinnamate (1)
- tongue (1)
- topical treatment (1)
- toxicity (1)
- track and trace (1)
- trametinib (1)
- transport (1)
- triacylglycerides (1)
- trypanosoma cruzi (1)
- type 2 diabetes (1)
- ultrafiltration (1)
- unnatural amino acid (1)
- unsaturated fatty acids (1)
- urolithins (1)
- ursolic acid (1)
- vacuoles (1)
- validation (1)
- valsartan (1)
- valtrates (1)
- veterinarians (1)
- veterinary medicine (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- volumetric absorptive microsampling (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (102) (remove)
Sonstige beteiligte Institutionen
- Apotheke, Universitätsklinikum Würzburg (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- Johns Hopkins School of Medicine (1)
- Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg (1)
- Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, DE-37077 Goetingen, Germany (1)
- Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland (1)
- Zentraleinheit Klinische Massenspektrometrie (1)
- Zentrallabor, Universitätsklinikum Würzburg (1)
EU-Project number / Contract (GA) number
- 26230120009 (1)
- 296679 (1)
- 314911 (1)
- 701983 (1)
Background
Even though the international combat against Neglected Tropical Diseases such as schistosomiasis or soil-transmitted helminthiases depends on reliable therapeutics, anthelminthic pharmacovigilance has been neglected on many national African drug markets. Therefore, quality and composition of Albendazole, Mebendazole and Praziquantel locally collected in Burkina Faso, Côte d’Ivoire, Ghana and Tanzania were analysed.
Methods
Samples of 88 different batches were obtained from randomly selected facilities. Sampling took place in Northwest Tanzania, Western Burkina Faso, Southeast Côte d’Ivoire and Southwest Ghana. Visual examination of both packaging and samples was performed according to the WHO ‘Be Aware’ tool. Products were then screened with the GPHF Minilab, consisting of tests of mass uniformity, disintegration times and thin-layer chromatography (TLC). Confirmatory tests were performed according to international pharmacopoeiae, applying assays for dissolution profiles and high-performance liquid chromatography (HPLC).
Findings
Despite minor irregularities, appearance of the products did not hint at falsified medicines. However, 19.6% of the brands collected in Ghana and Tanzania were not officially licensed for sale. Mass uniformity was confirmed in 53 out of 58 brands of tablets. 41 out of 56 products passed disintegration times; 10 out of the 15 failing products did not disintegrate at all. Evaluating TLC results, only 4 out of 83 batches narrowly missed specification limits, 18 batches slightly exceeded them. Not more than 46.3% (31 / 67) of the tablets assayed passed the respective pharmaceutical criteria for dissolution. HPLC findings confirmed TLC results despite shifted specification limits: 10 out of 83 tested batches contained less than 90%, none exceeded 110%.
Conclusion
In the four study countries, no falsified anthelminthic medicine was encountered. The active pharmaceutical ingredient was not found to either exceed or fall below specification limits. Galenic characteristics however, especially dissolution profiles, revealed great deficits.
Background
Genetic code expansion has developed into an elegant tool to incorporate unnatural amino acids (uAA) at predefined sites in the protein backbone in response to an amber codon. However, recombinant production and yield of uAA comprising proteins are challenged due to the additional translation machinery required for uAA incorporation.
Results
We developed a microtiter plate-based high-throughput monitoring system (HTMS) to study and optimize uAA integration in the model protein enhanced green fluorescence protein (eGFP). Two uAA, propargyl-L-lysine (Plk) and (S)-2-amino-6-((2-azidoethoxy) carbonylamino) hexanoic acid (Alk), were incorporated at the same site into eGFP co-expressing the native PylRS/tRNAPyl CUA pair originating from Methanosarcina barkeri in E. coli. The site-specific uAA functionalization was confirmed by LC-MS/MS analysis. uAA-eGFP production and biomass growth in parallelized E. coli cultivations was correlated to (i) uAA concentration and the (ii) time of uAA addition to the expression medium as well as to induction parameters including the (iii) time and (iv) amount of IPTG supplementation. The online measurements of the HTMS were consolidated by end point-detection using standard enzyme-linked immunosorbent procedures.
Conclusion
The developed HTMS is powerful tool for parallelized and rapid screening. In light of uAA integration, future applications may include parallelized screening of different PylRS/tRNAPyl CUA pairs as well as further optimization of culture conditions.
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (DDI). The goal of this work was to develop a physiologically based pharmacokinetic (PBPK) model to investigate EHC, to simulate DDI with Rifampin and to simulate subjects with hepatic impairment. The model was established using PK-Sim® and six human clinical studies. The inclusion of an EHC process into the model led to the most accurate description of the pharmacokinetic behavior of CAB. The model was able to predict plasma concentrations with low bias and good precision. Ninety-seven percent of all simulated plasma concentrations fell within 2-fold of the corresponding concentration observed. Maximum plasma concentration (C\(_{max}\)) and area under the curve (AUC) were predicted correctly (predicted/observed ratio of 0.9–1.2 for AUC and 0.8–1.1 for C\(_{max}\)). DDI with Rifampin led to a reduction in predicted AUC by 77%. Several physiological parameters were adapted to simulate hepatic impairment correctly. This is the first CAB model used to simulate DDI with Rifampin and hepatic impairment including EHC, which can serve as a starting point for further simulations with regard to special populations.
Considerable effort has previously been invested in a light‐controlled inhibition of the enzyme acetylcholinesterase (AChE). We found that a novel azobenzene‐based bistacrine AChE inhibitor switched faster than the known dithienylethene based bistacrine and inverted the photo‐controlled interactions of the photoisomers compared to its dithienylethene congener. Furthermore, we have optimized a previously described light‐controlled tacrine‐based AChE inhibitor. Isomerization upon irradiation with UV light of the novel inhibitor was observed in aqueous medium and showed no fatigue over several cycles. The cis‐enriched form showed an 8.4‐fold higher inhibition of hAChE compared with its trans‐enriched form and was about 30‐fold more active than the reference compound tacrine with a single‐digit nanomolar inhibition. We went beyond proof‐of‐concept to discover photoswitchable AChE inhibitors with pharmacologically desirable nanomolar inhibition, “cis‐on” effect, and pronounces differences between the photoisomers.
Therapeutic drug monitoring (TDM) is increasingly relevant for an individualized antibiotic therapy and subsequently a necessary tool to reduce multidrug-resistant pathogens, especially in light of diminishing antimicrobial capabilities. Critical illness is associated with profound pharmacokinetic and pharmacodynamic alterations, which challenge dose finding and the application of particularly hydrophilic drugs such as β-lactam antibiotics. Methods: Implementation strategy, potential benefit, and practicability of the developed standard operating procedures were retrospectively analyzed from January to December 2020. Furthermore, the efficacy of the proposed dosing target of piperacillin in critically ill patients was evaluated. Results: In total, 160 patients received piperacillin/tazobactam therapy and were subsequently included in the study. Of them, 114 patients received piperacillin/tazobactam by continuous infusion and had at least one measurement of piperacillin serum level according to the standard operating procedure. In total, 271 measurements were performed with an average level of 79.0 ± 46.0 mg/L. Seventy-one piperacillin levels exceeded 100 mg/L and six levels were lower than 22.5 mg/L. The high-level and the low-level group differed significantly in infection laboratory parameters (CRP (mg/dL) 20.18 ± 11.71 vs. 5.75 ± 5.33) and renal function [glomerular filtration rate (mL/min/1.75 m2) 40.85 ± 26.74 vs. 120.50 ± 70.48]. Conclusions: Piperacillin levels are unpredictable in critically ill patients. TDM during piperacillin/tazobactam therapy is highly recommended for all patients. Although our implementation strategy was effective, further strategies implemented into the daily clinical workflow might support the health care staff and increase the clinicians' alertness.
Pentacyclic triterpenes from Cecropia telenitida with immunomodulatory activity on dendritic cells
(2013)
Pentacyclic triterpenes are a large family of plant metabolites that exhibit a wide array of biological activities. The genus Cecropia, which encompasses many plant species, has been used as traditional medicine for the treatment of inflammatory diseases and is known to produce many active pentacyclic triterpenes. In this study we investigated the chemical composition of a pentacyclic triterpene fraction from the roots of Cecropia telenitida Cuatrec., Urticaceae. A novel compound, which we termed yarumic acid, and four known molecules (serjanic acid, spergulagenic acid A, 20-hydroxy-ursolic acid and goreishic acid I) were isolated and characterised. In a dendritic cell (DC)-based assay, we demonstrated that non-toxic doses of these pentacyclic triterpenes inhibited the secretion of at least one of the proinflammatory cytokines tested (IL-1 beta, IL-12p40, IL-12p70, TNF-alpha). Spergulagenic acid A also inhibited nitric oxide production in lipopolysaccharide-stimulated dendritic cell. Serjanic acid and spergulagenic acid A, which were the most potent abundant compounds in the pentacyclic triterpene fraction, showed the most activity in the dendritic cell-based assay. These results show that all pentacyclic triterpenes might contribute to the anti-inflammatory activities of C. telenitida. Moreover, yarumic acid as well as the four known pentacyclic triterpenes, can be exploited as potential immunomodulatory/anti-inflammatory agents.
Background
Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options show limited efficacy and high toxicity. Localization of the parasites inside host cells is a barrier to most standard chemo- and immune-based interventions. Hence, novel drugs, which are safe, effective and readily accessible to third-world countries and/or drug delivery technologies for effective CL treatments are desperately needed.
Methodology/Principal
Findings Here we evaluated the antileishmanial properties and delivery potential of polyhexamethylene biguanide (PHMB; polyhexanide), a widely used antimicrobial and wound antiseptic, in the Leishmania model. PHMB showed an inherent antileishmanial activity at submicromolar concentrations. Our data revealed that PHMB kills Leishmania major (L. major) via a dual mechanism involving disruption of membrane integrity and selective chromosome condensation and damage. PHMB's DNA binding and host cell entry properties were further exploited to improve the delivery and immunomodulatory activities of unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN). PHMB spontaneously bound CpG ODN, forming stable nanopolyplexes that enhanced uptake of CpG ODN, potentiated antimicrobial killing and reduced host cell toxicity of PHMB.
Conclusions
Given its low cost and long history of safe topical use, PHMB holds promise as a drug for CL therapy and delivery vehicle for nucleic acid immunomodulators.
The well-known Ugi reaction of aldehydes with amines, carboxylic acids and isocyanides leads to the formation of acyclic alpha-acylaminocarboxamides. Replacement of the carboxylic acid derivatives with beta-acyl substituted acrylic acids gives access to highly substituted 2,5-diketopiperazines in one single reaction-step without additives or complex reaction procedures. The obtained diketopiperazines show anti-proliferative effects on activated T cells and represent therefore potential candidates for targeting unwanted T cell-mediated immune responses.
In times of environmental change species have two options to survive: they either relocate to a new habitat or they adapt to the altered environment. Adaptation requires physiological plasticity and provides a selection benefit. In this regard, the Western honeybee (Apis mellifera) protrudes with its thermoregulatory capabilities, which enables a nearly worldwide distribution. Especially in the cold, shivering thermogenesis enables foraging as well as proper brood development and thus survival. In this study, we present octopamine signaling as a neurochemical prerequisite for honeybee thermogenesis: we were able to induce hypothermia by depleting octopamine in the flight muscles. Additionally, we could restore the ability to increase body temperature by administering octopamine. Thus, we conclude that octopamine signaling in the flight muscles is necessary for thermogenesis. Moreover, we show that these effects are mediated by β octopamine receptors. The significance of our results is highlighted by the fact the respective receptor genes underlie enormous selective pressure due to adaptation to cold climates. Finally, octopamine signaling in the service of thermogenesis might be a key strategy to survive in a changing environment.
The functional role of human gut microbiota has attracted substantial interest and recent research has uncovered various aspects of the interplay between the complex communities of microorganisms colonizing the intestine and their hosts’ health. The present review focuses on nutrition-derived bioactive metabolites produced by gut microbiota with potential beneficial effects upon human health. Thereby, the emphasis is on newly generated bacterial metabolites that are not concomitantly present at higher amounts in dietary sources and that have been previously detected in human blood samples. Since a multitude of different substances is generated by gut microbes primarily those metabolites which exert a more pronounced activity than their immediate precursor compound are discussed here. Specifically, the in vitro and in vivo nutridynamics as well as the nutrikinetics of equol, enterolactone / enterodiol, urolithins, 8-prenylnaringenin, 3,4-dihydroxyphenylacetic acid and 5-(3’,4’-dihydroxyphenyl)-g-valerolactone, the short-chain fatty acids butyrate, propionate and acetate, and indole-3-propionic acid are reviewed. Though the metabolites’ mechanism of action and the influence of health conditions on metabolite production are not always fully understood yet, there are many reasons to direct the attention to “gut health”. It could offer new options for preventing or treating a variety of disease states and nutrition-derived microbial products might inspire future drug development.